Literature DB >> 36069593

Multicomponent Pseudomonas aeruginosa Vaccines Eliciting Th17 Cells and Functional Antibody Responses Confer Enhanced Protection against Experimental Acute Pneumonia in Mice.

Mohammad Omar Faruk Shaikh1,2, Matthew M Schaefers1,2, Christina Merakou1,2, Marco DiBlasi1, Sarah Bonney1, Tiffany Liao1, David Zurakowski2,3, Margaret Kehl4, David E Tabor4, Antonio DiGiandomenico4, Gregory P Priebe1,2,5.   

Abstract

The Gram-negative pathogen Pseudomonas aeruginosa is a common cause of pneumonia in hospitalized patients. Its increasing antibiotic resistance and widespread occurrence present a pressing need for vaccines. We previously showed that a P. aeruginosa type III secretion system protein, PopB, elicits a strong Th17 response in mice after intranasal (IN) immunization and confers antibody-independent protection against pneumonia in mice. In the current study, we evaluated the immunogenicity and protective efficacy in mice of the combination of PopB (purified with its chaperone protein PcrH) and OprF/I, an outer membrane hybrid fusion protein, compared with immunization with the proteins individually either by the intranasal (IN) or subcutaneous (SC) routes. Our results show that after vaccination, a Th17 recall response from splenocytes was detected only in mice vaccinated with PopB/PcrH, either alone or in combination with OprF/I. Mice immunized with the combination of PopB/PcrH and OprF/I had enhanced protection in an acute lethal P. aeruginosa pneumonia model, regardless of vaccine route, compared with mice vaccinated with either alone or adjuvant control. Immunization generated IgG titers against the vaccine proteins and whole P. aeruginosa cells. Interestingly, none of these antisera had opsonophagocytic killing activity, but antisera from mice immunized with vaccines containing OprF/I, had the ability to block IFN-γ binding to OprF/I, a known virulence mechanism. Hence, vaccines combining PopB/PcrH with OprF/I that elicit functional antibodies lead to a broadly and potently protective vaccine against P. aeruginosa pulmonary infections.

Entities:  

Keywords:  OprF/I; PopB; Pseudomonas aeruginosa; Th17; immunization; pneumonia

Mesh:

Substances:

Year:  2022        PMID: 36069593      PMCID: PMC9584304          DOI: 10.1128/iai.00203-22

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.609


  46 in total

1.  Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia.

Authors:  Weihui Wu; Jin Huang; Biyan Duan; David C Traficante; Haeyeon Hong; Martina Risech; Stephen Lory; Gregory P Priebe
Journal:  Am J Respir Crit Care Med       Date:  2012-06-21       Impact factor: 21.405

2.  IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge.

Authors:  Shabaana A Khader; Guy K Bell; John E Pearl; Jeffrey J Fountain; Javier Rangel-Moreno; Garth E Cilley; Fang Shen; Sheri M Eaton; Sarah L Gaffen; Susan L Swain; Richard M Locksley; Laura Haynes; Troy D Randall; Andrea M Cooper
Journal:  Nat Immunol       Date:  2007-03-11       Impact factor: 25.606

3.  Intranasal immunization promotes th17 immune responses.

Authors:  Beata M Zygmunt; Faiza Rharbaoui; Lothar Groebe; Carlos A Guzman
Journal:  J Immunol       Date:  2009-11-04       Impact factor: 5.422

4.  Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid.

Authors:  Stefan Worgall; Anja Krause; Michael Rivara; Kyung-Kim Hee; Enrico V Vintayen; Neil R Hackett; Peter W Roelvink; Joseph T Bruder; Thomas J Wickham; Imre Kovesdi; Ronald G Crystal
Journal:  J Clin Invest       Date:  2005-04-01       Impact factor: 14.808

5.  Prevalence of type III secretion genes in clinical and environmental isolates of Pseudomonas aeruginosa.

Authors:  Heather Feltman; Grant Schulert; Salman Khan; Manu Jain; Lance Peterson; Alan R Hauser
Journal:  Microbiology       Date:  2001-10       Impact factor: 2.777

6.  A fusion protein vaccine containing OprF epitope 8, OprI, and type A and B flagellins promotes enhanced clearance of nonmucoid Pseudomonas aeruginosa.

Authors:  Eric T Weimer; Haiping Lu; Nancy D Kock; Daniel J Wozniak; Steven B Mizel
Journal:  Infect Immun       Date:  2009-04-06       Impact factor: 3.441

7.  A randomized, placebo-controlled phase I study assessing the safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein OprF/I vaccine (IC43) in healthy volunteers.

Authors:  Kerstin Westritschnig; Romana Hochreiter; Gerhard Wallner; Christa Firbas; Michael Schwameis; Bernd Jilma
Journal:  Hum Vaccin Immunother       Date:  2013-09-24       Impact factor: 3.452

8.  Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut.

Authors:  Manuela Raffatellu; Renato L Santos; David E Verhoeven; Michael D George; R Paul Wilson; Sebastian E Winter; Ivan Godinez; Sumathi Sankaran; Tatiane A Paixao; Melita A Gordon; Jay K Kolls; Satya Dandekar; Andreas J Bäumler
Journal:  Nat Med       Date:  2008-03-23       Impact factor: 53.440

Review 9.  Progress Toward the Elusive Pseudomonas aeruginosa Vaccine.

Authors:  Christina Merakou; Matthew M Schaefers; Gregory P Priebe
Journal:  Surg Infect (Larchmt)       Date:  2018-11-15       Impact factor: 2.150

10.  Immunogenic and antigenic properties of a heptavalent high-molecular-weight O-polysaccharide vaccine derived from Pseudomonas aeruginosa.

Authors:  K Hatano; S Boisot; D DesJardins; D C Wright; J Brisker; G B Pier
Journal:  Infect Immun       Date:  1994-09       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.